Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the transaction, the insider directly owned 26,250 shares in the company, valued at $723,975. This trade represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Stock Down 3.2%

NASDAQ MAZE opened at $26.57 on Tuesday. The business’s fifty day simple moving average is $28.76 and its 200-day simple moving average is $31.63. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market cap of $1.48 billion, a PE ratio of -10.54 and a beta of 2.22. Maze Therapeutics, Inc. has a 52 week low of $13.89 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, equities analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. BTIG Research reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $66.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its stake in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics during the 4th quarter valued at about $43,000. California State Teachers Retirement System boosted its holdings in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after acquiring an additional 766 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Maze Therapeutics in the 2nd quarter valued at about $48,000. Finally, Ameritas Investment Partners Inc. grew its position in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.